Skip to content

Patient Reported Outcome Measures in BRCA 1 or 2 mutation carriers

Patient Reported Outcome Measures in BRCA 1 or 2 mutation carriers

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON27474
Enrollment
100
Registered
2018-11-23
Start date
2018-11-26
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BRCA 1 or 2 gene mutation, bilateral prophylactic mastectomy, direct breast reconstruction, surveillance, health related quality of life bilaterale profylactische mastectomie, directe borst reconstructie, BRCA 1 of 2 genmutatie, gezondheid gerelateerde kwaliteit van leven

Interventions

BRCA 1 or 2 gene mutation carries who choose breast surveillance or bilateral prophylactic mastectomy with immediate reconstruction.

Sponsors

Prof. dr. J.M. Hendriks Head of Dept. of Surgery Erasmus University Medical Center Rg 226 P.O. 2040 3000 CA Rotterdam (T) 010-7031206
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) > 18 years 2) agreement with participation 3) adequate understanding of Dutch language

Exclusion criteria

Exclusion criteria: 1) no adequate understanding of Dutch language 2) time since surgery <1 year, 3) time in surveillance <1 year.

Design outcomes

Primary

MeasureTime frame
Patient reported outcome values considering different strategies in breast cancer prevention in woman with BRCA 1 or 2 mutations. Patients will be grouped according to the strategy performed, i.e. bilateral prophylactic mastectomy or breast surveillance. Values will be collected through the HADS and the BREAST-Q.

Contacts

Public ContactL.B. Koppert,

Department of Surgery, Erasmus MC Cancer Institute PO Box 5201

l.koppert@erasmusmc.nl(010-70)41161

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)